BIOMAT Database Logo BIOMAT Database Logo

Decreased arginine-induced HGH response during L-dopa therapy in parkinsonian patients. 1974

S E Johnson, and N Norman, and O Sjaastad

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate

Related Publications

S E Johnson, and N Norman, and O Sjaastad
[Response of growth hormone (HGH) to L-dopa, L-arginine and their combination in normal individuals].
January 1982, Medicina clinica,
S E Johnson, and N Norman, and O Sjaastad
[L-dopa therapy in Parkinsonian syndromes].
September 1970, Il Policlinico. Sezione pratica,
S E Johnson, and N Norman, and O Sjaastad
[HGH response to dihydroxyphenylalanine (L-dopa) (author's transl)].
January 1976, Anales espanoles de pediatria,
S E Johnson, and N Norman, and O Sjaastad
L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.
January 1977, Gerontology,
S E Johnson, and N Norman, and O Sjaastad
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
October 1974, Rivista di patologia nervosa e mentale,
S E Johnson, and N Norman, and O Sjaastad
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
August 2015, Brain research,
S E Johnson, and N Norman, and O Sjaastad
[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
January 1998, Therapie,
S E Johnson, and N Norman, and O Sjaastad
Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday.
January 1995, Journal of neural transmission. Supplementum,
S E Johnson, and N Norman, and O Sjaastad
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
January 1993, Advances in neurology,
S E Johnson, and N Norman, and O Sjaastad
[Clinical significance of long-term treatment of L-dopa with bromocriptine in parkinsonian patients who showed declining efficacy during L-dopa therapy].
March 1985, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!